H.R. 4818 118th Congress
Treat and Reduce Obesity Act of 2023
- Health
- Sponsor: Rep. Wenstrup, Brad R. [R-OH-2]
- Congress.gov ↗
Latest action, Dec 27, 2024: Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-959, Part I.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
120 cosponsors
Sponsored by Rep. Wenstrup, Brad R. [R-OH-2] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
91 D · 29 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
CURRAX PHARMACEUTICALS LLC
DLA PIPER LLP (US)
7 reports
6 reports
BOEHRINGER INGELHEIM USA CORPORATION
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
6 reports
ELI LILLY & COMPANY
WILLIAMS AND JENSEN, PLLC
6 reports
GERONTOLOGICAL SOCIETY OF AMERICA
NVG, LLC
6 reports
6 reports
6 reports
NOVO NORDISK INC.
AVOQ, LLC
6 reports
NOVO NORDISK INC.
WILLIAMS AND JENSEN, PLLC
6 reports
6 reports
5 reports
ELI LILLY AND COMPANY
BROWNSTEIN HYATT FARBER SCHRECK, LLP
5 reports
ELI LILLY AND COMPANY FKA LILLY USA, LLC
FORBES-TATE
5 reports
All 25 of 43 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| CURRAX PHARMACEUTICALS LLC | DLA PIPER LLP (US) | 7 | $570K | Q4 2023 | Q3 2024 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 6 | $17.3M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES INC.(FKA AMERICAN PSYCHOLOGICAL ASSN | 6 | $2.3M | Q4 2023 | Q3 2024 | yes | |
| AMGEN INC | 6 | $18.1M | Q4 2023 | Q3 2024 | yes | |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 6 | $6.6M | Q4 2023 | Q3 2024 | yes |
| ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| GERONTOLOGICAL SOCIETY OF AMERICA | NVG, LLC | 6 | $150K | Q4 2023 | Q3 2024 | yes |
| KAISER FOUNDATION HEALTH PLAN INC | 6 | $3.7M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL KIDNEY FOUNDATION | 6 | $725K | Q4 2023 | Q3 2024 | yes | |
| NOVO NORDISK INC. | AVOQ, LLC | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | 6 | $480K | Q4 2023 | Q3 2024 | yes |
| CHRONIC CARE POLICY ALLIANCE | 5 | $520K | Q4 2023 | Q3 2024 | yes | |
| ELI LILLY AND COMPANY | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| ELI LILLY AND COMPANY FKA LILLY USA, LLC | FORBES-TATE | 5 | $250K | Q4 2023 | Q3 2024 | yes |
| NOVO NORDISK, INC. | ARNOLD & PORTER KAYE SCHOLER LLP | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| ACADEMY OF NUTRITION AND DIETETICS (FORMERLY AS AMERICAN DIETETIC ASSOCIATION) | 4 | $60K | Q4 2023 | Q3 2024 | yes | |
| HEALTH EQUITY COALITION FOR CHRONIC DISEASE | NVG, LLC | 4 | $270K | Q1 2024 | Q3 2024 | yes |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 4 | $214K | Q1 2024 | Q3 2024 | yes | |
| NOVO NORDISK INC. | NVG, LLC | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| AMERICAN NEPHROLOGY NURSES ASSOCIATION | VENABLE LLP | 3 | $90K | Q4 2024 | Q3 2024 | yes |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 3 | $750K | Q4 2024 | Q3 2024 | yes | |
| ASSOCIATION OF BLACK CARDIOLOGISTS | SUMMIT HEALTH CARE CONSULTING | 3 | $45K | Q4 2023 | Q1 2024 | yes |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 3 | $5.1M | Q4 2024 | Q3 2024 | yes | |
| CAMBIA HEALTH SOLUTIONS | 3 | $1.9M | Q4 2024 | Q3 2024 | yes |